A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Status: Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel; Topotecan
- Indications Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms ROCSAN
- Sponsors ARCAGY/GINECO Group
- 03 Oct 2019 Planned End Date changed from 1 Jan 2023 to 1 Jun 2025.
- 03 Oct 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2024.
- 03 Oct 2019 Planned initiation date changed from 1 Jan 2019 to 1 Jan 2020.